Correspondence 0001447028-24-000092 from Arbutus Biopharma Corp (ABUS) (CIK 0001447028) (ABUS)
Arbutus Biopharma Corp (ABUS) (CIK 0001447028)
Date: Dec. 2, 2024 · CIK: 0001447028 · Accession: 0001447028-24-000092
AI Filing Summary & Sentiment
File numbers found in text: 333-283038
Letter
Document
ARBUTUS BIOPHARMA CORPORATION
701 Veterans Circle
Warminster, Pennsylvania 18974
December 2, 2024
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tyler Howes
Re: Arbutus Biopharma Corporation
Registration Statement on Form S-3
Filed November 6, 2024
File No. 333-283038
Request for Acceleration of Effective Date
To Whom it May Concern,
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Arbutus Biopharma Corporation hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 9:00 a.m., Eastern Time, on December 5, 2024, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642. Also, please notify Mr. Nicolai when this request for acceleration has been granted.
Very truly yours,
ARBUTUS BIOPHARMA CORPORATION
Show Raw Text
CORRESP
1
filename1.htm
Document
ARBUTUS BIOPHARMA CORPORATION
701 Veterans Circle
Warminster, Pennsylvania 18974
December 2, 2024
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tyler Howes
Re: Arbutus Biopharma Corporation
Registration Statement on Form S-3
Filed November 6, 2024
File No. 333-283038
Request for Acceleration of Effective Date
To Whom it May Concern,
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Arbutus Biopharma Corporation hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 9:00 a.m., Eastern Time, on December 5, 2024, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642. Also, please notify Mr. Nicolai when this request for acceleration has been granted.
Very truly yours,
ARBUTUS BIOPHARMA CORPORATION
By: /s/ David C. Hastings
Name: David C. Hastings
Title: Chief Financial Officer